[Role of rosuvastatin in current lipid-lowering therapy]
- PMID: 20719717
- DOI: 10.1556/OH.2010.28937
[Role of rosuvastatin in current lipid-lowering therapy]
Abstract
Statins are the most widely used lipid-lowering therapy. Among them, the rosuvastatin can be well tolerated and effectively helps to reach LDL-cholesterol goals in primary and secondary cardiovascular prevention. In addition, rosuvastatin reduces triglyceride and high-sensitivity C-reactive protein level and increases high-density lipoprotein (HDL) cholesterol, too. Imaging studies demonstrated that rosuvastatin therapy can not only reduce atherosclerosis progression but might induce its regression too.
Similar articles
-
Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial).Am J Cardiol. 2013 Feb 15;111(4):506-9. doi: 10.1016/j.amjcard.2012.10.037. Epub 2012 Dec 10. Am J Cardiol. 2013. PMID: 23237107 Clinical Trial.
-
Achievement rates of Japan Atherosclerosis Society Guidelines 2007 LDL-cholesterol goals with rosuvastatin or atorvastatin in patients who had not achieved their goal with atorvastatin.Cardiovasc Ther. 2014 Jun;32(3):97-104. doi: 10.1111/1755-5922.12066. Cardiovasc Ther. 2014. PMID: 24456217 Clinical Trial.
-
Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?Adv Ther. 2009 May;26(5):469-87. doi: 10.1007/s12325-009-0025-6. Epub 2009 May 14. Adv Ther. 2009. PMID: 19444394 Review.
-
Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.Clin Ther. 2004 Nov;26(11):1821-33. doi: 10.1016/j.clinthera.2004.11.015. Clin Ther. 2004. PMID: 15639694 Clinical Trial.
-
An update on the benefits and risks of rosuvastatin therapy.Postgrad Med. 2014 Mar;126(2):7-17. doi: 10.3810/pgm.2014.03.2736. Postgrad Med. 2014. PMID: 24685964 Review.
Cited by
-
Rosuvastatin suppresses platelet-derived growth factor-BB-induced vascular smooth muscle cell proliferation and migration via the MAPK signaling pathway.Exp Ther Med. 2013 Oct;6(4):899-903. doi: 10.3892/etm.2013.1265. Epub 2013 Aug 20. Exp Ther Med. 2013. Retraction in: Exp Ther Med. 2023 Nov 13;27(1):11. doi: 10.3892/etm.2023.12299. PMID: 24137286 Free PMC article. Retracted.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials